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Background: Locally advanced rectal cancer (LARC) is a heterogeneous group of tumors where a risk-adapted
therapeutic strategy is needed. Short-course radiotherapy (SCRT) is a more convenient option for LARC patients
than preoperative long-course RT plus capecitabine. Histone-deacetylase inhibitors (HDACi) have shown activity in
combination with RT and chemotherapy in the treatment of solid tumors. Valproic acid (VPA) is an anti-epileptic
drug with HDACi and anticancer activity. In preclinical studies, our group showed that the addition of HDACi,
including VPA, to capecitabine produces synergistic antitumour effects by up-regulating thymidine phosphorylase
(TP), the key enzyme converting capecitabine to 5-FU, and by downregulating thymidylate synthase (TS), the 5-FU
target.
Methods/Design: Two parallel phase-1 studies will assess the safety of preoperative SCRT (5 fractions each of 5 Gy,
on days 1 to 5) combined with (a) capecitabine alone (increasing dose levels: 500–825 mg/m2/bid), on days 1–21,
or (b) capecitabine as above plus VPA (oral daily day −14 to 21, with an intra-patient titration for a target serum
level of 50–100 microg/ml) followed by surgery 8 weeks after the end of SCRT, in low-moderate risk RC patients.
Also, a randomized phase-2 study will be performed to explore whether the addition of VPA and/or capecitabine to
preoperative SCRT might increase pathologic complete tumor regression (TRG1) rate. A sample size of 86 patients
(21-22/arm) was calculated under the hypothesis that the addition of capecitabine or VPA to SCRT can improve the
TRG1 rate from 5% to 20%, with one-sided alpha = 0.10 and 80% power.
Several biomarkers will be evaluated comparing normal mucosa with tumor (TP, TS, VEGF, RAD51, XRCC1, Histones/
proteins acetylation, HDAC isoforms) and on blood samples (polymorphisms of DPD, TS, XRCC1, GSTP1, RAD51 and
XRCC3, circulating endothelial and progenitors cells; PBMCs-Histones/proteins acetylation). Tumor metabolism will be
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measured by 18FDG-PET at baseline and 15 days after the beginning of SCRT.
Discussion: This project aims to improve the efficacy of preoperative treatment of LARC and to decrease the
inconvenience and the cost of standard long-course RT. Correlative studies could identify both prognostic and predictive
biomarkers and could add new insight in the mechanism of interaction between VPA, capecitabine and RT.
EudraCT Number: 2012-002831-28.
Trial registration: ClinicalTrials.gov number, NCT01898104.
Keywords: Rectal cancer, Short-course radiotherapy (SCRT), HDAC inhibitors, Valproic acid (VPA), FDG-PET, Preoperative
chemo-radiotherapyBackground
Hystone deacetylases (HDAC) enzymes and role of HDAC
inhibitors (HDACi) as anticancer agents
Histone deacetylases (HDACs) regulate the acetylation
of a variety of histone and nonhistone proteins, control-
ling the transcription and regulation of genes involved in
cell cycle control, proliferation, survival, DNA repair and
differentiation. HDAC expression is frequently altered in
hematologic and solid tumors [1].
Histone Deacetylase inhibitors (HDACi) represent a
new class of antitumor agents able to affect, based on the
function of the epigenetic enzymes they regulate, multiple
genes and pathways [1-4]. In particular, our group and
many others have demonstrated the synergistic antitumor
activity of HDACi in combination with a large number of
structurally diverse anticancer agents [2-5]. Many HDAC
inhibitors (HDACi) have demonstrated preclinical efficacy
as monotherapy or in combination with other anticancer
drugs for both hematological and solid malignancies.
However, clinical efficacy of HDACi, particularly in solid
tumors, remains not demonstrated, most likely because of
lack of understanding of the best context and combination
regimen for their clinical use.
Several HDACi are currently in clinical development as
anticancer agents and two (vorinostat and romidepsin)
have been approved by the US FDA for the treatment of
cutaneous T-cell lymphoma.
Valproic acid: preclinical and clinical studies
The anti-epileptic valproic acid (2-propylpentanoic acid,
VPA), an 8-carbon, branched-chained fatty acid, has
HDAC inhibitory activity. Independent of this property, it
is being used as an anticonvulsant agent and is clinically
effective as a mood stabilizer in the treatment of maniac
depression (bipolar affective disorder). The recommended
values of serum concentrations for the treatment of epi-
lepsy are in the 50–100 μg/ml range. Due to its HDAC
inhibiting activity and its safe use as a chronic therapy (for
over 40 years) for epileptic disorders, VPA has been con-
sidered a good candidate for anticancer therapy. In a large
series of preclinical studies, exposure to VPA results indose-dependent reversible cell cycle arrest and cell growth
inhibition as well as chromatin decondensation and cellu-
lar differentiation in several neoplastic cell models [6].
Several phase I and II studies of VPA in adults with
hematologic and solid malignancies showed that VPA
treatment, either as a monotherapy or combined with
other agents, was reasonably well tolerated and resulted
in some encouraging tumor responses.
VPA ability to inhibit deacetylase activity in solid tumors
has been demonstrated in monotherapy at oral doses bet-
ween 20 and 60 mg/kg [7]. VPA oral doses of 30 mg/kg
daily induced histone deacetylase inhibition in the peri-
pheral blood of locally advanced breast cancer patients
in a neoadjuvant therapy study in combination with the
demethylating agent hydralazine added to doxorubicin
and cyclophosphamide. The mean plasma concentration
was of 87.5 μg/ml, the therapy was safe and tumor re-
sponses appeared higher as compared with historical con-
trols [8].
In a phase I/II trial of VPA in combination with Epirubi-
cin or in combination with 5-Fluorouracil, Epirubicin, and
Cyclophosphamide (FEC100) for patients with solid tu-
mors, 44 patients received escalating doses of valproate
with a fixed dose of Epirubicin and the maximum tole-
rated dose (MTD) was 140 mg/kg/day with nine patients
achieving a partial response. During the second part of the
study, a disease-specific cohort of 15 breast cancer patients
were treated with 120 mg/kg/day Valproate and the com-
bination regimen FEC100. With nine out of 14 patients
responding to therapy. Overall, somnolence was the most
noted adverse effect related to VPA and the acetylation
levels measured in peripheral blood mononuclear cell
(PBMC) correlated with VPA serum levels and could be
linked to baseline HDAC2-but not HDAC6 expression [9].
VPA safety and cardiac toxicity
Common adverse effects associated with HDAC inhibitors
include thrombocytopenia, neutropenia, diarrhea, nausea,
vomiting and fatigue. Most toxicities are class-specific and
have been observed with all HDAC inhibitors. However,
differently from other HDAC inhibitors, VPA has a good
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toms (dizziness, confusion) as dose limiting toxicities
(DLTs), rather than fatigue [7-12].
A cardiac toxicity has been reported in several studies
with other HDAC inhibitors [13-17]. In a phase I trial of
VPA in combination with Epirubicin, a grade 2 QTc pro-
longation was reported in eight patients (18%), and a
grade 3 QTc prolongation was seen in two patients (5%);
these events occurred predominantly on day 1 of VPA
treatment. QTc prolongations were associated with se-
rum potassium levels less than 4.0 mmol/L and were re-
solved in all patients with appropriate potassium and
magnesium supplementation [10].
Rationale for the combination of an HDAC inhibitor with
fluoropyrimidines and radiotherapy
Multiple HDAC inhibitors have been shown to affect ra-
diosensitivity in preclinical models including VPA [18].
HDAC inhibitor vorinostat has been recently safely com-
bined with short-term pelvic palliative radiotherapy in
gastrointestinal neoplasms including rectal cancers [19]. A
clinical trial combining VPA, radiation, and chemotherapy
for children with high-grade gliomas reported that three
times daily administrations, to maintain trough concen-
trations of 75 to 100 μg/ml of VPA, was well tolerated
in children with refractory solid or central nervous sys-
tem (CNS) tumors. Histone hyperacetylation in PBMCs
was observed in half of the patients at steady state [20].
Moreover, a retrospective analysis of the dataset for the
EORTC/NCIC chemo-radiotherapy trial with temozo-
lamide and radiotherapy (RT) in newly diagnosed glio-
blastoma suggested that concomitant treatment with VPA
might be associated with a prolonged survival [21].
In vitro and in vivo studies from our group and others,
conducted in models of colon, head and neck and breast
cancers, showed that treatment with HDACi is associ-
ated with the downregulation of thymidylate synthase
(TS), the key enzyme in the mechanism of action of
5-Fluorouracil (5-FU) [5]. Moreover, we have recently
demonstrated, for the first time, that HDACi vorinostat
in combination with capecitabine produces a synergistic
antitumor effects by up-regulating, in vitro and in vivo,
in colorectal cancer cells but not in ex vivo treated
peripheral blood lymphocytes, the mRNA and protein
expression of thymidine phosphorylase (TP), the key
enzyme converting capecitabine to 5-FU [2]. We con-
firmed a time and dose-dependent inhibition of TS and
induction of TP mRNA and protein expression by
several other HDACi, including VPA [2]. We investi-
gated potential antitumor interaction between capecita-
bine metabolite 5′-deoxy-5-fluorouridine (5′-DFUR) and
several HDACi showing synergistic/additive antiprolife-
rative and proapoptotic effects in all cancer cells tested,
with better results with VPA [22].Interestingly, TP protein induction is achieved also at
low doses of VPA (0.3-0.7 mM), corresponding to a
plasma level between 50 and 100 μg/ml, easily reached in
patients with normal anticonvulsant doses. Although at
these doses VPA did not induce growth inhibition as sin-
gle agents, a significant synergistic antitumor effect was
still demonstrated in combination with 5′-DFUR, sugges-
ting a specific mechanism of interaction [22]. TP knock-
down experiments confirmed a crucial role of TP protein
modulation in the observed synergism [2]. Moreover,
washout experiments showed that the induction of TP,
mediated by VPA treatment, is still evident 24 h after drug
removal, suggesting the feasibility of a sequential-schedule
of combination treatment [22].
Definition of rectal cancer with low-moderate risk of
recurrence
The shift from a postoperative to a preoperative chemo-
radiotherapy (CRT) approach and the wide adoption of
total mesorectal excision (TME) have remarkably im-
proved the management of locally advanced rectal can-
cer (LARC), resulting in a significant improvement of
local control [23]. Moreover, preoperative CRT, com-
pared with postoperative CRT, significantly decreased
acute and late toxicity, and increased preservation of
sphincter function [23]. In the last years, because distant
metastases have become the predominant pattern of fail-
ure in rectal cancer, the integration of new antineoplastic
agents into preoperative fluoropyrimidine-based CRT
has been studied. However, results from clinical trials,
including randomized phase III trials, have showed dis-
appointing results. Therefore, several novel strategies
with different sequence of multimodal treatment compo-
nents are being evaluated.
The evidence that LARC is a widely heterogeneous
group of tumors with different prognostic behaviour
[24], suggests that a risk-adapted therapeutic strategy
should be pursued in this disease. Tumor (T) extension
and lymph node (N) involvement represent important
prognostic factors for recurrence-free and overall sur-
vival [25]. More recently, a prognostic role has also
emerged for the circumferential resection margin (CRM)
involvement that identifies patients with worse prognosis
[26]. Moreover, the worse prognosis of patients with dis-
tal (less than 5 cm from the anal verge) rectal cancer has
also been ascribed to the higher frequency of CRM
involvement, occurring for the natural “coning-in” of the
mesorectum in this location [27]. Currently, CRM in-
volvement can be predicted by measuring the infiltration
of perirectal fat from the mesorectal fascia (MRF) with
high resolution magnetic resonance imaging (MRI);
therefore, this test plays an important role in staging rec-
tal cancer, because it may help to define patients prog-
nosis. However, similarly to other imaging techniques,
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ments is limited. For this reason the management of
clinical T3N0 is still controversial and preoperative RT
or CRT is warranted for this subgroup of rectal cancer
patients, despite the risk of overtreating early-stage
disease [28].
Besides reducing local recurrence and improving sur-
vival, an additional goal in the treatment of rectal cancer
is to perform conservative surgery, that can be safely in-
dicated to patients with early T stage and node-negative
cancer. However, the goal of sphincter preservation can
be also pursued in more advanced cases, initially candi-
dated to abdominal-perineal resection, thanks to pre-
operative RT [29].
Altogether, these findings suggest that, cT2N0 tumors
located at <2 cm from anal verge, T2N1 or T3N0- N1
tumors, located at >5 cm from anal verge and with infil-
tration of perirectal fat >5 mm from MRF evaluated by
MRI, can be categorized as a group of rectal cancer with
low-moderate risk of recurrence, in which preoperative
RT can be considered a valid option.
Preoperative short-course radiotherapy
Radiotherapy has been extensively used in rectal cancer
during the past decades to reduce the risk of a local fail-
ure, even if radical surgery seems feasible or has already
been performed, or to increase the chances of a radical
(R0) resection in a locally advanced tumour. In the first
situation, a hypofractionated short-course radiotherapy
(SCRT) followed with immediate surgery is an option
supported by randomized trials, since no down-sizing or
down-staging is required [30,31]. In the second situation,
conventionally fractionated long-course RT (1.8 Gy/frac-
tion up to a final dose of 45 – 50.4 Gy) is used, followed
by surgery 6 to 8 weeks later, to allow both the recovery
from acute radiation-induced tissue reactions and tumor
downstaging. Concomitant chemotherapy, 5-FU/capeci-
tabine given along with the long-course RT improves
local control [32-34] and it is thus a standard treatment
for patients who are suitable for this combined therapy.
SCRT without chemotherapy has been compared with
long-course CRT in two recent randomized studies and
no statistically differences in recurrence rates and sur-
vival have been found [35,36]. A Polish trial showed no
difference in local recurrence rate and survival compar-
ing conventional radiotherapy scheme (50.4 Gy, surgery
after 4–6 weeks) combined with chemotherapy (5-FU/
Leucovorin) with short-term preoperative radiotherapy
(5 × 5 Gy, surgery within 7 days), although more down
staging occurred with the former scheme [35]. Similar
results were reported from a recent Australian trial [36].
An ongoing trial (Stockholm III) is randomizing patients
with resectable rectal cancer to either long-course RT
(50 Gy), SCRT with immediate surgery or SCRT withdelayed surgery (4–8 weeks “waiting period”) and, re-
cently, data from an interim analysis including 300 pa-
tients demonstrated that SCRT with delayed surgery is
feasible [37]. Retrospective observational data have shown
that SCRT with delayed surgery can produce significant
downstaging and also pathological complete response
(pCR) in some patients, with low toxicity [38-40]. In a trial
including also M1 patients, systemic chemotherapy was
administered after SCRT before surgery and no significant
local tumor progression during chemotherapy was seen
while in 11 of 41 resected rectal specimens a pathologic
complete response was observed [41]. Altogether these
data suggest that pre-operative SCRT with delayed surgery
is feasible and that down-staging or down-sizing may
occur following this regimen.
On this basis, and considering that SCRT is logistically
convenient and cheaper when compared with CRT, it is
interesting to assess the safety and efficacy of preope-
rative SCRT plus fluoropyrimidine-based chemotherapy
followed by delayed surgery in patients with resectable
rectal with low-moderate risk of recurrence.Rationale for the biologic pharmacogenetic and
pharmacokinetic study
Histone acetylation in tumor samples and in PBMC cor-
related in several studies with VPA serum levels and
were also further linked to baseline expression of some
HDAC isoforms (i.e. HDAC2 but not HDAC6) [9,42].
As mentioned above the synergism between HDACi
and fluoropyrimidines seems explained by the modula-
tion of the expression of TS and TP. Polymorphism of
Dihydropyrimidine deydrogenase (DPD) gene or TS gene
may affect toxicity and activity of fluoropyrimidines.
HDACi can regulate the expression of DNA repair genes
such as RAD51 [43]. Polymorphisms in genes regulating
DNA repair, such as XRCC1 (Arg399Gln), GSTP1 (lle105-
Val) RAD51 (135G >C) and XRCC3 (Thr241Met and
4541A >G), may affect activity and toxicity of radiotherapy.
Several reports demonstrated that circulating endothe-
lial cells (CECs) levels are increased in the peripheral
blood of cancer patients at diagnosis, and that chemo-
therapy can reduce the amounts of mature viable CECs
determining the return to normal values in patients
undergoing complete remission. In particular, Bertolini
and colleagues have recently demonstrated that CEC
count and viability could represent a promising predic-
tive factor for anti-angiogenic therapies [44].Methods/Design
V-shoRT-R3 is a phase I/2 trial exploring the safety and
the activity of capecitabine given alone or with VPA,
during preoperative SCRT in patient with low-moderate
risk rectal cancer.
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The primary objective of the Phase I study is to de-
termine the MTD of capecitabine given alone or in
combination with valproic acid during preoperative
SCRT.
The primary objective of the phase II comparative
study is to explore whether the addition of valproic
acid and/or capecitabine to SCRT before optimal
radical surgery might increase the rate pathologic
complete tumor regression (reported as tumor regres-
sion grade 1; TRG1) in patients with low-moderate risk
rectal cancer.
Within each planned phase II comparison, secondary
objectives include the evaluation of local control, dis-
ease free survival and overall survival, pathological
CRM negative (>1 mm) and lymph node negative rate,
short and long-term toxicity, surgical complications,
and quality of life. The study also aims to validate
the predictive role of early tumor metabolic changes
measured by positron emission tomography (PET) scan
(both phase I and II) and to assess the diagnostic ac-
curacy of pre-surgical rectal biopsy, performed after
the induction of anaesthesia in all surgical operations
and analysed by intraoperative pathology (both phase I
and II).
A translational sub-study is also planned, within the
phase II trial, with several aims: (a) to compare the ex-
pression of several biomarkers (TP, TS, VEGF, RAD51,
XRCC1, Histones and proteins acetylation, HDAC iso-
forms) in the tumor and normal mucosa, at baseline
and at different time points during and after treatment;
(b) to analyse polymorphisms of genes that may affect
activity and toxicity of chemo-radiotherapy (DPD, TS,
XRCC1, GSTP1, RAD51 and XRCC3) on DNA from
peripheral blood; (c) to evaluate Circulating Endothelial
Cells (CEC) and Progenitors (CEP) counts on peripheral
blood at baseline and at different time points during and
after treatment; (d) to evaluate Histones and proteins
acetylation (H&P-Ac) of PBMCs at baseline and at dif-
ferent time points during and after treatment.
Ethical aspects
The procedures set out in this study protocol are de-
signed to ensure that the principles of the Good Clinical
Practice guidelines of the International Conference on
Harmonization (ICH) and the Declaration of Helsinki
are respected in the conduct, evaluation and documen-
tation of this study.
The study was approved by the Ethical Committee of
the National Cancer Institute of Naples, Italy, and by the
National Institute of Health, as required by the Italian
regulation on Phase I clinical trials. Patients provide writ-
ten informed consent for participating in the study and
for allowing to collect tissue and blood samples.Study design
Phase I
Two parallel phase I studies will be performed (Figure 1a)
with capecitabine, given on days 1 to 21, concomitantly and
after SCRT (5 fractions each of 5 Gy, on days 1 to 5), as sin-
gle agent (V- trial) or in combination with VPA (V + trial)
(orally daily from day −14 to 21, with an intra-patient
titration for a target serum level of 50–100 μg/ml that is
considered useful to produce the synergistic effect with
radio- and/or chemotherapy).
Four increasing dose levels of capecitabine (L1-L4) are
planned: 500, 650, 750, and 825 mg/m2/bid. Three fur-
ther intermediate dose levels (L1b, L2b, L3b), are also
provided in case MTD is reached (Figure 1a).
At each dose level, a cohort of 3 patients (pts) will be
enrolled. Within each trial, MTD will be defined as
the dose producing DLT in 2 pts (any grade 3 non-
hematologic or grade 4 hematologic toxicity occurring
within 5 weeks from day 1 of treatment).
Patients will be enrolled consecutively according to
the available slot. However, the V + trial will begin after
the enrollment of the first 2 cohorts in the V- trial. Sub-
sequent cohorts in the V + trial will be enrolled only with
dose levels of capecitabine that have not been defined as
MTD in the V- trial.
The dose level immediately lower than the MTD will
be the recommended phase II dose (RP2D); within each
study, the cohort treated at the RP2D will be expanded
up to 9 pts.
According to the study design, and if MTD is reached
or not, sample size of each phase I study will vary from
2 to 33 pts.
Patients eligible at a time when phase I studies are still
ongoing but a treatment slot is not available will be of-
fered to enter the first time-window of the phase II trial
(see below).
Phase II
The randomized phase II multicentre study will have
two distinct time windows: the first one while phase I
studies are ongoing and the second one after phase I
studies have defined the RP2D of capecitabine (C) with-
out and with VPA (V- and V+) (Figure 1b).
In the first window, randomization will be 1:1 to
2 arms, SCRT and V/SCRT, with patients randomized
when a phase I slot is not available at the time of
their inclusion. Its duration depends on the dura-
tion of phase I studies and there is no definite sam-
ple size.
In the second window, randomization will be 1:1:1:1 to
4 arms: SCRT; V/SCRT; C/SCRT CV/SCRT (Figure 1b).
The primary endpoint of the phase II study is the
TRG1 rate according to Mandard modified scoring sys-
tem [45], after definitive surgery.
L1 V- L2 V- L3 V- L4 V-notMTD
not
MTD
not
MTDV- trial
2 DLT2 DLT2 DLT
L1b V- L2b V- L3b V-
notMTD
and L3 V- notMTD
notMTD
and L4 V-
cohort enrolled cohort enrolled
L1 V+ L2 V+ L3 V+ L4 V+
not MTD
and L2 V-
cohort enrolled
not
MTD
not
MTD
not
MTDV+ trial
2 DLT2 DLT2 DLT
L1b V+ L2b V+ L3b V+
C-SCRTC-SCRT
Phase 1 slot
il bl Phase 1 sequenalava a e
CV-SCRTCV-SCRT
SecondFirst me
window Randomme
(phase2)window
SCRTSCRT
Phase 1 slot
not available Randomizedphase 2
V-SCRTV-SCRT
a
b
Figure 1 V-shoRT-R3 study design. a) Scheme of phase I study, b) Plan of Phase II study.
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two separate comparisons, according to the following
scheme:
a) to test the effect of capecitabine: SCRT + V/SCRT vs
C/SCRT + CV/SCRT;
b) to test the effect of VPA: SCRT + C/SCRT vs
V/SCRT + CV/SCRT.
Sample size for phase II study is calculated for the sec-
ond time window. In details, a sample size of 86 patients
(approximately 21–22 pts assigned to each arm) is planned
under the hypothesis that the addition of capecitabine or
VPA to SCRT can improve the TRG1 rate from 5% to 20%,
with one-sided alpha = 0.10 (that is 0.20 corrected for the
2 planned comparisons) and 80% power. Patients random-
ized during the first time window, will be added to the
analysis of the effect of valproic acid; as a consequence,
the statistical power of such comparison will be increased
and more reliable estimates of treatment toxicity will be
produced. Randomization will be performed with a mini-
mization procedure that will account for centre, clinical N
stage (N0 vs N1) and clinical T stage (T2 vs T3).Patient selection criteria
Inclusion criteria
Patients ≥18 and ≤70 years, diagnosed with adenocarcin-
oma of rectum defined at low-moderate risk of recurrence
by T and N extension but also on the basis of CRM
involvement measured by MRI: cT2N0 tumors located
at ≤2 cm from anal verge, T2N1 or T3N0- N1 tumors,
located at >5 cm from anal verge and with infiltration of
perirectal fat >5 mm from MRF evaluated by MRI. ECOG
Performance Status ≤1. Effective contraception for both
male and female patients if the risk of conception exist.
Signed written informed consent.
Exclusion criteria
Any previous pelvic radiotherapy or treatment for rectal
cancer. Presence of metastatic disease or recurrent rectal
tumor. History of inflammatory bowel disease or active dis-
ease. Any concurrent malignancy. Inadequate bone mar-
row, liver or renal function (Neutrophils <2000/mm3 or
platelets <100.000/ mm3 or haemoglobin <9 gr/dl; Creatin-
ine levels indicating renal clearance of <50 ml/min; GOT
and/or GPT >2.5 time the upper-normal limits, UNL; and/
or bilirubin >1.5 time UNL). Significant cardiovascular
Avallone et al. BMC Cancer 2014, 14:875 Page 7 of 12
http://www.biomedcentral.com/1471-2407/14/875comorbidity. Patients with long QT-syndrome or QTc
interval duration >480 msec or concomitant medication
with drugs prolonging QTc. Patients who cannot take oral
medication.
Patient who have had prior treatment with an HDACi
and patients who have received compounds with HDACi-
like activity, such as valproic acid. Known or suspected
hypersensitivity to any of the study drugs. Concurrent un-
controlled medical conditions that might contraindicate
study drugs. Major surgical procedure, within 28 days
prior to study treatment start. Pregnant or lactating
women.
Treatment plan
Treatment with VPA will not be matter of dose-finding
but a titration strategy will be applied in each patient loo-
king for a serum concentration that is considered useful
to produce the desired synergistic effect with radiotherapy
and/or chemotherapy. Treatment will be administered or-
ally starting at day −14, until day 21 from beginning of
radiotherapy, with a 500 mg slow releasing tablet at eve-
ning (Figure 2). Thereafter, the dose will be increased also
using 300 mg tablets (Table 1). In the morning of day −4,B
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tion seen at ECG on day -11)
*patient treated with VPA only, 
only in patients with QT prolungation
# patients enrolled in the four-arm phase 2 only
*
#
*
* *
#
*
* #
#
ysical examination, blood count, biochemistry will be repeated weekly
Table 1 Valproic acid titration scheme
Days Morning dose* Midday dose* Evening dose*
−14 & -13 0 0 500
−12 & -11 300 0 500
−10 & -9 500 0 500
−8 & -7 500 300 500
−6 & -5 500 500 500
−4 & -3 500 500 500
−2 & -1 500 500 500
*The interval between doses will be 12 hours on days −14 to −9 and 8 hours
from day −8.
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http://www.biomedcentral.com/1471-2407/14/875825 mg/m2/bid, for 21 days starting on the day before the
beginning of radiotherapy. During the phase II study, cape-
citabine will be administered at the daily dose indicated as
RP2D within phase I studies. This dose might be different
without and with VPA, according to results of phase I
studies. Toxicity due to capecitabine will be managed by
25% dose-reduction in case of grade 2 adverse events.
Treatment with capecitabine will be interrupted upon the
occurrence of a grade ≥3 adverse event and restarted once
the adverse event has resolved or decreased in intensity to
grade 1. The dose will be maintained after the 1st occur-
rence of the event and will be reduced by 25% at each sub-
sequent occurrence up to a maximum of 50%. Treatment
should be discontinued after the 4th occurrence of the
event.
RT will be administered according to a short course
hypofractionated scheme (SCRT) consisting of five frac-
tions each of 5 Gy for 5 consecutive days for a total dose
of 25 Gy.
Both in phase I and II studies, surgical operation, will
be performed 8 weeks after the last day of radiotherapy.
To explore diagnostic accuracy of pre-surgical rectal bi-
opsy, all surgical operations will include a preliminary
rectal biopsy, that will be performed after the induction
of anaesthesia. The biopsy specimen will be examined
intraoperatively; however, the result of intraoperative
pathology will not influence subsequent surgical be-
haviour. An anterior resection or an abdominal perineal
resection, with total mesorectal excision, will be per-
formed on the basis of restaging. Fecal diversion to pro-
tect the anastomosis will be performed by the means of
a loop ileostomy; and ileostomy reversal will be performed
after endoscopic assessment of anastomotic integrity. All
resection specimens will be examined by two independent
dedicated rectal cancer pathologists and pathologic sta-
ging, ypTNM and TRG, will be determined according to
AJCC guidelines [48]. The number of examined/involved
lymph nodes, tumor differentiation, lymphatic and venous
invasion, and status of proximal, distal, and circumferen-
tial resection margins will be also reported.Assessment and procedures
Assessment and procedures, including those for explora-
tory objectives (see below), are illustrated in Figure 2.
Adverse events
Adverse events will be graded according to the Common
Terminology Criteria for Adverse events of the National
Cancer Institute (CTCAE-NCI) version 4.0.
Adverse events will be assessed at the following times:
at baseline (within 3 weeks before the initiation of any
treatment), at days 8, 15, 22, 29, before surgery, 1 and
2 months after surgery. In addition, only in patients re-
ceiving VPA, adverse events will be assessed at day −4.
FDG-Positron Emission Tomography (PET) imaging
MRI and other conventional imaging modalities such as
EUS and CT are unable to differentiate post-radiation
inflammation and fibrotic changes from viable tumor
in the residual lesion following preoperative treatment
[49,50]. In contrast, metabolic imaging with [18 F] 2-
fluoro-2-deoxy-D-glucose positron emission tomography
(FDG-PET) may be more valuable in this respect as the
high glycolitic activity of tumor cells can be utilized to
discriminate fibrosis from viable tumor tissue [51]. In
the neoadjuvant setting, a strong correlation between
FDG standardized uptake value (SUV) changes and
pathologic response has been demonstrated in different
tumors [52-54], including rectal cancer [55]. Our group
has previously reported that early metabolic change eval-
uated by FDG-PET is able to predict pathologic tumor
response [56] and outcome [57] in rectal cancer. Thus,
FDG-PET/CT scans are planned at baseline and on day
11 (+/− 2) in patients enrolled in phase II study, to vali-
date the ability of early metabolic change to predict
TRG and outcome. For each tumor volume, maximal
standardized uptake value (SUV-max, the maximum
pixel value in the lesion), SUV-mean (the average SUV
value in the lesion) and Total Lesion Glycolisis (TLG,
SUV-mean x metabolic tumor volume) will be calcu-
lated. A responder patient, consistent with our previous
studies, will be define according to reduction of SUV or
TLG parameters of 50% or more compared to baseline.
Therefore, patients with any change below this threshold
will be defined as non-responder. Further thresholds will
be eventually explored only in case of failure (lack of
predictive ability) of the proposed validation.
Pharmacodynamic, pharmacogenetic and
pharmacokinetic studies on tumor and blood samples
Tumor and normal mucosa samples will be collected
only in patients enrolled in the four-arm phase II study:
at baseline (possibly within the diagnostic rectal biopsy)
and at surgery for all patients and at day −4 in patients
assigned VPA.
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XRCC1, will be compared with normal mucosa and with
tumor expression at the following time points as pharma-
codynamic/predictive markers of treatments (analyzed by
real-time PCR and immunohystochemistry). In fact, as re-
ported above, several evidences, by our group and others,
including preliminary results, suggested a crucial role of
the modulation of the expression of TS and TP in the syn-
ergism observed between HDACi and fluoropyrimidine.
On the other hand, TP showed a strong sequence hom-
ology to the pro-angiogenic platelet derived endothelial
cell growth factor (PD-ECGF), and may contribute to
angiogenesis, tumor progression and metastasis. However,
several reports have clearly shown that HDACi inhibit
tumor-induced angiogenesis by regulating VEGF pro-
duction and signaling. Moreover, the expression DNA re-
pair genes, such as RAD51 or XRCC1, affecting sensitivity
to RT and or chemotherapeutics, can be also regulated by
HDACi.
Histones and proteins acetylation (H&P-Ac) measured
at all the time points and HDAC isoforms evaluated at
baseline represent additional pharmacodynamic/predictive
specific markers of VPA HDACi activity.
Peripheral blood samples will be collected at baseline,
on day −4, 1, 8, 11, 22 and at surgery. VPA serum level
will be measured by a valproate test at all time points and
correlated with H&P-Ac, measured on peripheral PBMC
as additional surrogate pharmacodynamic markers of VPA
activity by multiparametric flowcytometry.
Polymorphisms of genes that may affect activity and
toxicity of radio-chemotherapy such as DPD, TS, XRCC1,
GSTP1, RAD51 and XRCC3, will be analyzed on baseline
samples by pyrosequencing technology.
Circulating Endothelial Cells (CEC) and Progenitors
(CEP) counts will be analyzed as surrogate marker of
tumor angiogenesis at baseline, on day 1, 11 and at sur-
gery by multiparametric flowcytometry.
Quality of life assessment
Quality of Life (QoL) will be assessed in patients enrolled
in the randomized four arm phase II study by the EORTC
QLQ-C30, version 3.0, and the EORTC QLQ-CR29
questionnaires that will be filled in by patients before
treatment, at the end of radiotherapy (D8) and of
chemotherapy (D22), before surgery and 30 days after
surgery [58,59].
Adjuvant treatment
There is no general agreement on the benefit of adju-
vant CT after preoperative CRT. The only study,
EORTC trial 22921, to formally evaluate the benefit
of adjuvant CT after preoperative CRT failed to
demonstrate a significant impact on survival of post-
operative chemotherapy [33]. Moreover, emerging datasuggest a significant correlation between pathologic
response to preoperative chemo-radiotherapy and on-
cologic outcomes, evidencing the favorable prognostic
value of pathologic complete response [60-62]. These
data generate the hypothesis that it might be reason-
able to link the decision on adjuvant treatment to the
pathologic response obtained after neoadjuvant treat-
ment. However, given the absence of definitive evi-
dence on this topic, and considering that the impact
of adjuvant treatment in this protocol will only affect
secondary end-points, decision regarding adjuvant chemo-
therapy will be decided by the investigators according to
the policy commonly adopted by their Institution in cli-
nical practice.Follow up
Patients will have follow-up evaluation every three
months for three years and every six months during
the following two years. Patients who have discontin-
ued study treatment for reasons other than progres-
sive disease will enter follow-up.Statistical analysis of phase II
Phase II analysis will be performed according to the
intention-to-treat strategy. Analyses will be performed
separately for the two planned comparisons. In each
comparison, TRG1 rate is defined as the rate of patients
out of those randomized who will experience a complete
pathological regression according to Mandard modified
scoring system (responders). Patients who will not
achieve a TRG1 will be defined as non-responders. Pa-
tients who will not undergo primary surgery because of
progressive disease will be defined as non-responders.
TRG1 rates will be compared with chi-square test in a
2×2 contingency table (responders/non-responders x
treatment arms).
For each patient and for each type of toxicity, the
worst degree suffered during treatment will be used
for the analysis. Two sets of statistical analyses will
be performed to compare toxicity. In the first set the
whole pattern of toxicity (all grades) will be consi-
dered for each item; analysis will be done by a linear
rank test. In the second set toxicity will be defined as
severe (mostly including grade 3 or higher) and not
severe (mostly including grades up to 2) and analysis
will be performed by Fisher’s exact test.
Due to the small sample size, statistical analysis of
biomarkers data will be conducted with the aim of
hypothesis generation. Biomarkers that might change
over time as a consequence of treatment, levels before
and after treatment will be compared with appro-
priate statistical tests, based on the type of data.
QoL will be described according to EORTC rules [58,59].
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The goal of the study is to demonstrate the feasibility
and explore the activity of a preoperative treatment with
SCRT, a very convenient modality of RT, in combination
with capecitabine and/or VPA, in patients with low-
moderate risk rectal cancer, and to identify potential
biomarkers predictive of toxicity and efficacy for these
combinations.
To date, the optimal preoperative management of RC
remains controversial regarding RT fractionation, timing
of surgery and use of concurrent chemotherapy.
Although preoperative SCRT has been assumed as a
valid option in resectable RC, with similar outcome but
low acute toxicity compared to long-course chemo-RT,
only one recent study investigate the feasibility of SCRT
plus 5FU [63]. Thus, our study is the first to investigate
both feasibility and activity of SCRT plus Cap. We will also
test for the first time the addition of VPA, a safe and low
cost generic drug with HDACi activity, to SCRT ± Cap.
This approach might improve the efficacy of preopera-
tive treatment of LARC and decrease its inconvenience
and cost as compared to the standard long-course chemo-
radiotherapy.
We will also evaluate mechanistically-based pharmaco-
kinetic/pharmacodynamic biomarkers on tumor and
blood samples and the predictive role of early (within
11 days after the beginning of SCRT) tumor metabolic
changes measured by 18FDG-PET/TC in patients under-
going phase II trial. These correlative studies could iden-
tify both prognostic and predictive biomarkers and could
add new insight in the mechanism of interaction between
VPA, capecitabine and RT. Furthermore, the identification
of biomarkers predictive of pathologic tumor regression,
including early tumor metabolic changes measured by
18FDG-PET/TC, could improve the selection of patients
candidate to a conservative surgical approach, which rep-
resent a major goal, considering the morbidity of total
mesorectal excision and its impact on patients quality of
life and costs.
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